This is the authors' abstract. We don't add key points for this paper.
In the near future, increasingly complex nanoparticle vaccines displaying multiple antigens and/or co-delivered adjuvants will reach clinical trials. An improved mechanistic understanding of nanoparticle vaccination will ultimately facilitate the rational design of improved vaccines for human health.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: